Connor, Clark & Lunn Investment Management (CC&L)’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-82,791
| Closed | -$2.87M | – | 1604 |
|
|
2024
Q2 | $2.87M | Sell |
82,791
-10,395
| -11% | -$360K | 0.01% | 560 |
|
|
2024
Q1 | $2.7M | Sell |
93,186
-14,356
| -13% | -$415K | 0.01% | 593 |
|
|
2023
Q4 | $2.47M | Sell |
107,542
-31,952
| -23% | -$733K | 0.01% | 616 |
|
|
2023
Q3 | $2.33M | Sell |
139,494
-23,931
| -15% | -$399K | 0.01% | 576 |
|
|
2023
Q2 | $4.51M | Buy |
163,425
+41,401
| +34% | +$1.14M | 0.02% | 419 |
|
|
2023
Q1 | $2.81M | Sell |
122,024
-72,680
| -37% | -$1.67M | 0.02% | 486 |
|
|
2022
Q4 | $2.12M | Buy |
194,704
+3,511
| +2% | +$38.3K | 0.01% | 526 |
|
|
2022
Q3 | $1.61M | Buy |
+191,193
| New | +$1.61M | 0.01% | 539 |
|
|
2020
Q3 | – | Sell |
-28,598
| Closed | -$505K | – | 1085 |
|
|
2020
Q2 | $505K | Buy |
+28,598
| New | +$505K | ﹤0.01% | 755 |
|